0001639643-19-000003.txt : 20190129 0001639643-19-000003.hdr.sgml : 20190129 20190129172147 ACCESSION NUMBER: 0001639643-19-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190129 DATE AS OF CHANGE: 20190129 EFFECTIVENESS DATE: 20190129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kalytera Therapeutics, Inc. CENTRAL INDEX KEY: 0001639643 IRS NUMBER: 471374952 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-331679 FILM NUMBER: 19549571 BUSINESS ADDRESS: STREET 1: 4040 CIVIC CENTER DRIVE, SUITE 200 CITY: SAN RAFAEL STATE: CA ZIP: 94903 BUSINESS PHONE: 888-861-2008 MAIL ADDRESS: STREET 1: 4040 CIVIC CENTER DRIVE, SUITE 200 CITY: SAN RAFAEL STATE: CA ZIP: 94903 D 1 primary_doc.xml X0708 D LIVE 0001639643 Kalytera Therapeutics, Inc. 4040 CIVIC CENTER DRIVE, SUITE 200 SAN RAFAEL CA CALIFORNIA 94903 888-861-2008 BRITISH COLUMBIA, CANADA None None Corporation true 2016 Robert Farrell 4040 Civic Center Drive, Suite 200 San Rafael CA CALIFORNIA 94903 Executive Officer Director Ronald Erickson 4040 Civic Center Drive, Suite 200 San Rafael CA CALIFORNIA 94903 Director Gary Leong 4040 Civic Center Drive, Suite 200 San Rafael CA CALIFORNIA 94903 Director Jeff Paley 4040 Civic Center Drive, Suite 200 San Rafael CA CALIFORNIA 94903 Director Victoria Rudman 4040 Civic Center Drive, Suite 200 San Rafael CA CALIFORNIA 94903 Executive Officer Other Decline to Disclose 06b false 2019-01-22 false true true true false 0 Alere Financial Partners, a division of Cova Capital Partners LLC 109761 None None 6851 Jericho Turnpike, Suite 120A Syosset NY NEW YORK 11791 CA CALIFORNIA CO COLORADO MA MASSACHUSETTS false 338333 145000 193333 The estimated amounts are based on CAD$1.3234/USD$1.00 exchange rate. The Total Offering Amount includes the aggregate exercise price of USD$193,333 in respect of unexercised warrants issued as part of the offering. false 3 12733 true 0 The estimated amount is based on CAD$1.3234/USD$1.00 exchange rate PLUS 204,687 common share purchase warrants. 0 false Kalytera Therapeutics, Inc. /s/ Robert Farrell Robert Farrell President, CEO and Director 2019-01-29